Search Results - "Frohman, E M"

Refine Results
  1. 1

    Evidence-based guideline: Clinical evaluation and treatment of transverse myelitis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology by SCOTT, T. F, FROHMAN, E. M, DE SEZE, J, GRONSETH, G. S, WEINSHENKER, B. G

    Published in Neurology (13-12-2011)
    “…To assess the evidence for diagnostic tests and therapies for transverse myelitis (TM) and make evidence-based recommendations. A review of the published…”
    Get full text
    Journal Article
  2. 2

    Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis by ZIVADINOV, R, REDER, A. T, FILIPPI, M, MINAGAR, A, STÜVE, O, LASSMANN, H, RACKE, M. K, DWYER, M. G, FROHMAN, E. M, KHAN, O

    Published in Neurology (08-07-2008)
    “…Disease-modifying agents (DMAs), including interferon beta (IFNbeta) and glatiramer acetate (GA), are the mainstays of long-term treatment of multiple…”
    Get full text
    Journal Article
  3. 3

    Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis by GORDON-LIPKIN, E, CHODKOWSKI, B, REICH, D. S, SMITH, S. A, PULICKEN, M, BALCER, L. J, FROHMAN, E. M, CUTTER, G, CALABRESI, P. A

    Published in Neurology (16-10-2007)
    “…Optical coherence tomography (OCT) noninvasively quantifies retinal nerve fiber layer (RNFL) thickness. Studies show RNFL thinning in multiple sclerosis (MS),…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence : Report report of the therapeutics and technology assessment subcommittee of the american academy of neurology by GOODIN, D. S, FROHMAN, E. M, HURWITZ, B, O'CONNOR, P. W, OGER, J. J, REDER, A. T, STEVENS, J. C

    Published in Neurology (27-03-2007)
    “…The clinical and radiologic impact of developing neutralizing antibodies (NAbs) to interferon beta (IFNbeta) while on this therapy for multiple sclerosis (MS)…”
    Get full text
    Journal Article Conference Proceeding
  6. 6

    Quantitative sensory testing: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology by SHY, M. E, FROHMAN, E. M, SO, Y. T, AREZZO, J. C, CORNBLATH, D. R, GIULIANI, M. J, KINCAID, J. C, OCHOA, J. L, PARRY, G. J, WEIMER, L. H

    Published in Neurology (25-03-2003)
    “…This assessment evaluates the clinical utility, efficacy, and safety of quantitative sensory testing (QST). By searching MEDLINE, Current Contents, and their…”
    Get full text
    Journal Article
  7. 7

    Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy by STÜVE, O, CRAVENS, P. D, MACMANUS, D, MILLER, D. H, RADÜ, E. W, CAMERON, E. M, MONSON, N. L, ZHANG, S, KIM, R, HEMMER, B, FROHMAN, E. M, PHILLIPS, J. T, REMINGTON, G. M, VON GELDERN, G, CEPOK, S, SINGH, M. P, COHEN TERVAERT, J. W, DE BAETS, M

    Published in Neurology (03-02-2009)
    “…Natalizumab is a humanized recombinant monoclonal antibody against very late activation antigen-4 approved for the treatment of patients with multiple…”
    Get full text
    Journal Article
  8. 8

    The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology by GOODIN, D. S, ARNASON, B. G, COYLE, P. K, FROHMAN, E. M, PATY, D. W

    Published in Neurology (25-11-2003)
    “…Mitoxantrone is the first drug approved for the treatment of secondary progressive multiple sclerosis (SPMS) in the United States. This assessment considers…”
    Get full text
    Journal Article
  9. 9

    Pearls & Oy-sters: The medial longitudinal fasciculus in ocular motor physiology by Frohman, T C, Galetta, S, Fox, R, Solomon, D, Straumann, D, Filippi, M, Zee, D, Frohman, E M

    Published in Neurology (22-04-2008)
    “…To review the role played by the medial longitudinal fasciculus (MLF) in ocular motor physiology and to characterize a number of syndromes that result from…”
    Get full text
    Journal Article
  10. 10
  11. 11

    Modeling Uhthoff's phenomenon in MS patients with internuclear ophthalmoparesis by DAVIS, S. L, FROHMAN, T. C, CRANDALL, C. G, BROWN, M. J, MILLS, D. A, KRAMER, P. D, STÜVE, O, FROHMAN, E. M

    Published in Neurology (25-03-2008)
    “…The goal of this investigation was to demonstrate that internuclear ophthalmoparesis (INO) can be utilized to model the effects of body temperature-induced…”
    Get full text
    Journal Article
  12. 12

    Multiple sclerosis and the urologist by Litwiller, S E, Frohman, E M, Zimmern, P E

    Published in The Journal of urology (01-03-1999)
    “…We provide an updated reference detailing the neurological and urological state of the art approach to multiple sclerosis (MS) with special emphasis on the…”
    Get more information
    Journal Article
  13. 13

    Retinal architecture predicts pupillary reflex metrics in MS by Salter, AR, Conger, A, Frohman, TC, Zivadinov, R, Eggenberger, E, Calabresi, P, Cutter, G, Balcer, L, Frohman, EM

    Published in Multiple sclerosis (01-04-2009)
    “…Objective To study the relation of retinal nerve fiber layer thinning to clinical and physiologic measures of visual function in patients with MS or…”
    Get full text
    Journal Article
  14. 14

    MRI characteristics of the MLF in MS patients with chronic internuclear ophthalmoparesis by FROHMAN, E. M, ZHANG, H, KRAMER, P. D, FLECKENSTEIN, J, HAWKER, K, RACKE, M. K, FROHMAN, T. C

    Published in Neurology (11-09-2001)
    “…The authors imaged the medial longitudinal fasciculus (MLF) in 58 patients with MS and chronic internuclear ophthalmoparesis (INO) to determine which MRI…”
    Get full text
    Journal Article
  15. 15

    Cup to disc ratio by optical coherence tomography is abnormal in multiple sclerosis by Syc, S.B, Warner, C.V, Saidha, S, Farrell, S.K, Conger, A, Bisker, E.R, Wilson, J, Frohman, T.C, Frohman, E.M, Balcer, L.J, Calabresi, P.A

    Published in Journal of the neurological sciences (15-03-2011)
    “…Abstract Objective To identify and characterize cup to disc ratio (CDR) and related optic nerve head abnormalities in multiple sclerosis (MS) using spectral…”
    Get full text
    Journal Article
  16. 16

    The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis by Devonshire, V., Lapierre, Y., Macdonell, R., Ramo-Tello, C., Patti, F., Fontoura, P., Suchet, L., Hyde, R., Balla, I., Frohman, E. M., Kieseier, B. C.

    Published in European journal of neurology (01-01-2011)
    “…Background:  Most disease‐modifying therapies (DMTs) for multiple sclerosis (MS) are self‐injectable medications that must be taken on an ongoing basis to…”
    Get full text
    Journal Article
  17. 17
  18. 18

    Accuracy of clinical detection of INO in MS: Corroboration with quantitative infrared oculography by FROHMAN, T. C, FROHMAN, E. M, ZEE, D, CORBETT, J, CORBOY, J, RIVERA, V. M, KRAMER, P. D, O'SUILLEABHAIN, P, SALTER, A, DEWEY, R. B, HOGAN, N, GALETTA, S, LEE, A. G, STRAUMANN, D, NOSEWORTHY, J

    Published in Neurology (23-09-2003)
    “…The authors compared the accuracy of clinical detection (by 279 physician observers) of internuclear ophthalmoparesis (INO) with that of quantitative infrared…”
    Get full text
    Journal Article
  19. 19
  20. 20

    Benign paroxysmal positioning vertigo in multiple sclerosis: diagnosis, pathophysiology and therapeutic techniques by Frohman, E M, Kramer, P D, Dewey, R B, Kramer, L, Frohman, T C

    Published in Multiple sclerosis (01-06-2003)
    “…Objective: To report on the most common causes of vertigo in patients with multiple sclerosis (MS) and emphasize appro priate diagnostic techniques and…”
    Get full text
    Journal Article